ライフサイエンスコーパス: glyburide

1 or absence of metformin or the sulfonylurea glyburide.

2 effects are abolished by the K(ATP) blocker glyburide.

3 l activity or by UDP-induced displacement of glyburide.

4 lished by pretreatment with the KATP blocker glyburide.

5 inhibition by low concentrations of ATP and glyburide.

6 limepiride, and 1.04 (95% CI, 0.83-1.24) for glyburide.

7 ke volume and the potential efficacy of i.v. glyburide.

8 tion, randomized to a placebo or intravenous glyburide.

9 it of a reduction in swelling by intravenous glyburide.

10 by caspase-1 inhibition or the diabetes drug glyburide.

11 tissue explants, an effect also prevented by glyburide.

12 time with rosiglitazone versus metformin or glyburide.

13 rosiglitazone, as compared with metformin or glyburide.

14 iglitazone, 21% with metformin, and 34% with glyburide.

15 and 3 studies (n = 421) to metformin versus glyburide.

16 cardiac myocytes, which could be blocked by glyburide.

17 o alter the inhibition of K(ATP) channels by glyburide.

18 to characterize the in vitro metabolites of glyburide.

19 s were abolished by the KATP channel blocker glyburide (1 micromol/L).

20 rmin treatment groups; all subjects received glyburide (10 mg BID) as well.

21 Glyburide (10-100 nm) at basal glucose stimulated [3H]th

22 The oral ingestion of glyburide (5 mg) did not change mean arterial pressure (

23 uced relaxation defects were not improved by glyburide (50-300 micromol/l).

24 .7%) for DPP4i, 8.4% (95% CI, 6.8%-9.9%) for glyburide, 8.6% (95% CI, 7.9%-9.2%) for glimepiride, and

25 Glyburide, a K(ATP) channel inhibitor, reproduced the kn

26 Results were consistent for both glyburide (aHR, 1.26 [CI, 1.16 to 1.37]) and glipizide (

27 5% CI 0.96-1.42; aHR(Optum) 0.84, 0.65-1.08; glyburide: aHR(Medicaid) 0.87, 0.74-1.03; aHR(Optum) 1.1

28 Glyburide also blocks cytokine-induced eosinophil supero

29 a superoxide dismutase-mimetic agent) and by glyburide (an inhibitor of potassium efflux).

30 imately 3 nM, for an iodinated derivative of glyburide, an anti-diabetic sulfonylurea.

31 Glyburide, an inhibitor of ATP-sensitive K+ channels (K(

32 ges in cytosolic Ca2+, we determined whether glyburide, an inhibitor of K(ATP) channels that stimulat

33 Glyburide analogues inhibit ATP- but not hypothermia-ind

34 was 41 participants who received intravenous glyburide and 36 participants who received placebo.

35 This paper examines the effects of glyburide and 5-HD on K+ flux in isolated, respiring mit

36 w that mitoKATP is completely insensitive to glyburide and 5-HD under the experimental conditions in

37 er hand, mitoKATP became highly sensitive to glyburide and 5-HD when the open state was induced by Mg

38 and for the blocking of cardioprotection by glyburide and 5-hydroxydecanoate (5-HD).

39 Two inhibitors of anion transport, glyburide and ethacrynic acid, blocked maturation of bot

40 Cardiac mitoKATP channel high-affinity (glyburide and glipizide) and low-affinity (gliclazide an

41 were no significant differences between the glyburide and insulin groups in the percentage of infant

42 perinatal outcomes between those initiating glyburide and insulin.

43 cals that antagonize these fluxes, including glyburide and verapamil, also inhibit inflammasome activ

44 4.0 years with rosiglitazone, metformin, or glyburide and were examined with periodic metabolic test

45 de, 14 282 started glimepiride, 1887 started glyburide, and 13 849 started a DPP4i.

46 econd-generation sulfonylureas: glimepiride, glyburide, and glipizide.

47 t by KATP channel blockers, the sulfonylurea glyburide, and the cyanoguanidine N-[1-(3-chlorophenyl)c

48 Interestingly, the effects of glyburide are not antagonized by the ATP-sensitive K+ ch

49 ts, principally metformin and glibenclamide (glyburide), are also used in some countries.

50 erior glycemic durability over metformin and glyburide as initial monotherapy in type 2 diabetes.

51 We evaluated rosiglitazone, metformin, and glyburide as initial treatment for recently diagnosed ty

52 ed levels of low-, but not high-affinity [3H]glyburide binding in most forebrain areas.

53 g/min in awake rats reduced low-affinity [3H]glyburide binding in numerous hypothalamic and amygdalar

54 In DR-prone rats, low affinity [3H]glyburide binding sites comprised up to 45% of total bin

55 Although Scatchard analysis of [3H]glyburide binding to eosinophil membranes indicated that

56 the number of neurons and high-affinity [3H]glyburide binding was decreased by 20%, while 6-OHDA had

57 By contrast, high affinity [3H]glyburide binding was increased in DR rats throughout th

58 High affinity [3H]glyburide binding was similar between phenotypes.

59 re, glucose often increased low-affinity [3H]glyburide binding, particularly in DR-prone rats at 5 mM

60 Neither 6-OHDA nor 5,7-DHT affected [3H]glyburide binding, while ibotenic acid reduced the numbe

61 Such FC efflux was resistant to glyburide but inhibited by okadaic acid and vanadate.

62 ight gain and edema than either metformin or glyburide but with fewer gastrointestinal events than me

63 00 births lower after continuous exposure to glyburide compared with insulin.

64 xamined between patients with GDM initiating glyburide compared with those initiating insulin.

65 rugs such as glibenclamide (adopted US name, glyburide) confer protection against swelling and HT thr

66 N neurons, both 10 mM glucose and 100 microM glyburide decreased the open probability of the Katp cha

67 d high levels of ABC-1 transporter mRNA, and glyburide-dependent PL and FC efflux to apolipoprotein A

68 er with reduced lean mass versus insulin- or glyburide-exposed groups, independent of maternal glycae

69 Glyburide-exposed neonates had a nonsignificant increase

70 Glyburide-exposed neonates were heavier at birth (58.20

71 /m3, 95% CI -0.17 to -0.01, p = 0.03) versus glyburide-exposed neonates.

72 95% CI 0.08-1.19, I2 = 0%, p = 0.09) versus glyburide-exposed neonates.

73 Specifically, glyburide failed to inhibit spontaneous K[ATP] channel a

74 nt acceptance; however, the effectiveness of glyburide for the treatment of GDM remains controversial

75 Given the widespread use of glyburide, further investigation of these differences in

76 The channel blockers glyburide, gadolinium, or tetraethylammonium-Cl did not

77 Glyburide (GLB) is an antidiabetic drug routinely used t

78 ndil, and P1075 or the K(ATP) channel closer glyburide (glibenclamide).

79 the antidiabetic sulfonylurea (SU) compound glyburide (GLY) on energy metabolism, Na(+) flux, insuli

80 Eight women in the glyburide group (4 percent) required insulin therapy.

81 isk of cesarean delivery was 3% lower in the glyburide group (adjusted RR = 0.97; 95% CI, 0.93-1.00).

82 deciliter (5.9+/-0.9 mmol per liter) in the glyburide group and 105+/-18 mg per deciliter (5.9+/-1.0

83 deciliter (6.4+/-1.1 mmol per liter) in the glyburide group and 116+/-22 mg per deciliter (6.5+/-1.2

84 17 (41%) patients in the intravenous glyburide group and 14 (39%) in the placebo group had an

85 (23%) of 44 participants in the intravenous glyburide group and ten (26%) of 39 participants in the

86 rious adverse events (two in the intravenous glyburide group and two in the placebo group, p=1.00).

87 peptide concentrations were increased in the glyburide group compared with glipizide GITS in the 20-m

88 ocate patients to the placebo or intravenous glyburide group.

89 ected in the cord serum of any infant in the glyburide group.

90 Studies on glyburide have indicated that this drug is inactive in i

91 Oral agents, such as glyburide, have several advantages over insulin for the

92 glycemic control compared with metformin and glyburide in patients with recently diagnosed type 2 dia

93 ihyperglycemic durability than metformin and glyburide in patients with recently diagnosed type 2 dia

94 ions from other rats were incubated with [3H]glyburide in the presence of 0, 5 or 10 mM glucose.

95 binding autoradiographically with 20 nM [3H]glyburide in the presence of absence of Gpp(NH)p.

96 nding assessed autoradiographically with [3H]glyburide in the presence or absence of Gpp(NH)p.

97 ceptor autoradiographic binding of 20 nM [3H]glyburide (in the presence or absence of Gpp(NH)p which

98 SUR1 by sulfonylureas such as glibenclamide (glyburide) in conditions as seemingly diverse as stroke

99 [ATP] channels toward the sulfonylurea drug, glyburide, in the presence of cytosolic UDP.

100 e ATP-regulated potassium channel antagonist glyburide increased the rate of [3H]P1075 dissociation i

101 hibited by cotreatment with the KATP blocker glyburide, indicating that the KATP opening is involved

102 Oral glyburide ingestion partially restored CBR-mediated vaso

103 curves were similar at rest before and after glyburide ingestion.

104 The addition of glyburide inhibited diazoxide from increasing outflow fa

105 IL-3 or granulocyte-macrophage CSF overcome glyburide inhibition.

106 The sulfonylurea glyburide inhibits eosinophil survival even at high conc

107 In women with gestational diabetes, glyburide is a clinically effective alternative to insul

108 ggesting that the response of the channel to glyburide is phosphorylation dependent.

109 Therefore, glyburide is the first identified compound to prevent Cr

110 Glyburide is thought to be safe for use during pregnancy

111 In these open states, glyburide (K1/2 values 1-6 microM) and 5-HD (K1/2 values

112 means of green fluorescence probe BODIPY-FL-glyburide labeling of the sulfonylurea receptor of mitoK

113 oculture of eosinophils with combinations of glyburide, lidocaine, and dexamethasone resulted in syne

114 f UDP to antagonize the inhibitory action of glyburide lost after rundown, suggesting that the respon

115 des hypothesis-generating evidence that i.v. glyburide may improve outcome in large-core stroke <125

116 These data demonstrate that, unlike glyburide, metformin provides cardioprotection against H

117 ith GDM, 9173 women (8.3%) were treated with glyburide (n = 4982) or insulin (n = 4191).

118 Furthermore, the effects of glyburide on EGP and gluconeogenic enzymes were abolishe

119 Depolarization of beta cells with glyburide or 50 m potassium dramatically increased insul

120 UR1-TRPM4 using either the FDA-approved drug glyburide or 9-phenanthrol, as well as either constituti

121 Subjects were randomly assigned to glyburide or glipizide gastrointestinal therapeutic syst

122 ween 11 and 33 weeks of gestation to receive glyburide or insulin according to an intensified treatme

123 mitriptyline) and antihyperglycemics such as glyburide or insulin cause weight gain, and clinicians s

124 Treatment with glyburide or insulin during pregnancy within 150 days be

125 (mean [SD] age, 32.9 [4.9] years) initiated glyburide or insulin during pregnancy.

126 as exacerbated after systemic treatment with glyburide or nateglinide, KATP channel antagonists clini

127 h a sulfonylurea (glimepiride, glipizide, or glyburide) or a DPP4i (reference category) as a second l

128 -induced insulin release (by glucose, GLP-1, glyburide, or fatty acid) was approximately 60-70% lower

129 cies randomised to treatment with metformin, glyburide, or insulin were included.

130 and suggest that combination therapies with glyburide, or other inhibitors of the NLRP3 inflammasome

131 an metformin and with less hypoglycemia than glyburide (P<0.001 for all comparisons).

132 ed with metformin, and 63%, as compared with glyburide (P<0.001 for both comparisons).

133 Elevation of [Ca(2+)](i) by glyburide potentiated Erk-1/2 phosphorylation, which was

134 study, we show that the type 2 diabetes drug glyburide prevented activation of the Cryopyrin inflamma

135 ment with nifedipine or the K(ATP) inhibitor glyburide prevented insulin action, further implicating

136 models of stroke have shown that intravenous glyburide reduces brain swelling and improves survival.

137 Maternal randomisation to glyburide resulted in heavier neonates with a propensity

138 ast, chronic exposure to elevated glucose or glyburide resulted in progression from G0/G1 to an accum

139 duces significant hyperpolarization which is glyburide-reversed, thus consistent with the activation

140 emic functional recovery in a glibenclamide (glyburide)-reversible manner.

141 These agents were glyburide-reversible potassium channel openers and hyper

142 We assessed whether intravenous glyburide (RP-1127; glibenclamide) would safely reduce b

143 Glyburide's cyclohexylurea group, which binds to adenosi

144 ges in DiBAC(4)(3) fluorescence responses or glyburide-sensitive whole cell currents.

145 t with the role of Cryopyrin in endotoxemia, glyburide significantly delays lipopolysaccharide-induce

146 contrast, antagonism of K(ATP) channels with glyburide significantly reduced the EGP-lowering effect

147 ed calcium influx in response to glucose and glyburide, suggesting an insulin secretion defect either

148 effect was greater between rosiglitazone and glyburide than between rosiglitazone and metformin.

149 Type 2 diabetic subjects failing glyburide therapy were randomized to receive additional

150 corporation with chronic elevated glucose or glyburide therefore appears to be associated with S phas

151 mized to receive troglitazone 800 mg q.d. or glyburide titrated to achieve glycemic control (< or =20

152 IL1 receptor antagonist to block IL1beta or glyburide to block the Nlrp3 inflammasome results in dec

153 Rosiglitazone was added to insulin or glyburide to improve elevated hemoglobin Hb A1C levels i

154 The i.v. glyburide-treated participants had a favorable shift in

155 ho underwent endovascular thrombectomy, i.v. glyburide-treated subjects had a favorable outcome (adju

156 acid was, however, enhanced in SUR1(-/-) and glyburide-treated SUR1(+/+) islets.

157 efect in type 2 diabetic subjects who failed glyburide treatment by the addition of troglitazone (600

158 min versus insulin, 8 studies (n = 1,722) to glyburide versus insulin, and 3 studies (n = 421) to met

159 r, 4.9 mmol/L [88 mg/dL] for a 20-mg dose of glyburide vs 8.3 mmol/L [150 mg/dL] for placebo; nadir,

160 Time-varying exposure to glyburide vs insulin during pregnancy.

161 no statistically significant differences in glyburide vs insulin initiation in risk for neonatal hyp

162 used to evaluate associations of exposure to glyburide vs insulin with perinatal outcomes.

163 iations with SCA/VA for both glimepiride and glyburide (vs.

164 The risk difference associated with glyburide was 2.97% (95% CI, 1.82-4.12) for neonatal int

165 Glyburide was associated with a lower risk of cardiovasc

166 Intravenous glyburide was given as a 0.13 mg bolus intravenous injec

167 trations were similar in the two groups, and glyburide was not detected in the cord serum of any infa

168 r insulin secretagogues such as arginine and glyburide was similar to that of aP2+/+ mice, arguing ag

169 Intravenous glyburide was well tolerated in patients with large hemi

170 at baseline, newborns of women treated with glyburide were at increased risk for neonatal intensive

171 from privately insured mothers treated with glyburide were more likely to experience adverse outcome

172 ere are limited data on the effectiveness of glyburide when compared with insulin as used in a real-w

173 confidence intervals for the association of glyburide with diagnosis codes for obstetric trauma, ces